Ascendis Pharma A/S (NASDAQ:ASND) Rating Reiterated by Morgan Stanley

Morgan Stanley restated their equal weight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND - Free Report) in a research report report published on Monday, Benzinga reports. Morgan Stanley currently has a $116.00 price target on the biotechnology company's stock.

A number of other brokerages have also issued reports on ASND. Wells Fargo & Company increased their price target on Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an overweight rating in a research note on Friday, March 15th. Cantor Fitzgerald reiterated an overweight rating and issued a $173.00 price target on shares of Ascendis Pharma A/S in a research note on Thursday. JPMorgan Chase & Co. increased their price target on Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an overweight rating in a research note on Tuesday, April 2nd. StockNews.com upgraded Ascendis Pharma A/S from a sell rating to a hold rating in a research note on Monday, December 25th. Finally, Wedbush raised their price objective on Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an outperform rating in a research report on Thursday, February 8th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of Moderate Buy and an average target price of $173.25.

Ascendis Pharma A/S Trading Up 1.4 %

Ascendis Pharma A/S stock traded up $1.93 during trading on Monday, reaching $142.10. The company had a trading volume of 245,698 shares, compared to its average volume of 371,878. Ascendis Pharma A/S has a 52 week low of $66.03 and a 52 week high of $161.00. The firm's 50-day simple moving average is $149.12 and its 200 day simple moving average is $125.10. The firm has a market capitalization of $8.27 billion, a price-to-earnings ratio of -15.36 and a beta of 0.50.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.15) by $0.49. Ascendis Pharma A/S had a negative return on equity of 16,574.15% and a negative net margin of 180.61%. The business had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. On average, analysts predict that Ascendis Pharma A/S will post -4.15 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the business. Westfield Capital Management Co. LP lifted its holdings in shares of Ascendis Pharma A/S by 6.0% in the 4th quarter. Westfield Capital Management Co. LP now owns 4,030,634 shares of the biotechnology company's stock valued at $507,658,000 after acquiring an additional 228,457 shares during the last quarter. Avoro Capital Advisors LLC lifted its holdings in shares of Ascendis Pharma A/S by 2.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 3,755,555 shares of the biotechnology company's stock valued at $473,012,000 after acquiring an additional 85,555 shares during the last quarter. Capital International Investors lifted its holdings in shares of Ascendis Pharma A/S by 0.6% in the 4th quarter. Capital International Investors now owns 2,181,268 shares of the biotechnology company's stock valued at $274,731,000 after acquiring an additional 12,825 shares during the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Ascendis Pharma A/S by 20.1% in the 4th quarter. Massachusetts Financial Services Co. MA now owns 1,519,219 shares of the biotechnology company's stock valued at $191,346,000 after acquiring an additional 254,749 shares during the last quarter. Finally, TimesSquare Capital Management LLC lifted its holdings in shares of Ascendis Pharma A/S by 9.8% in the 3rd quarter. TimesSquare Capital Management LLC now owns 842,801 shares of the biotechnology company's stock valued at $78,920,000 after acquiring an additional 75,374 shares during the last quarter.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.